Psychiatric medication management typically involves brief appointments, 15 to 30 minutes, spaced weeks or months apart. In that short window, psychiatrists must assess symptom status, evaluate side effects, consider medication adjustments, and make prescribing decisions that will affect the patient for weeks.
This model has obvious limitations. Patients don't remember how they felt three weeks ago. Symptom patterns between appointments go undetected. Side effects that emerged and resolved are forgotten. The psychiatrist makes decisions based on a snapshot when they need a trajectory.
Digital assessments between appointments change this. Systematic data collection throughout the treatment period gives psychiatrists continuous visibility into patient status, enabling more informed and more timely medication management.
The evidence for measurement-based care
The data is compelling. A randomized controlled trial found that patients receiving measurement-based care achieved response rates of 86.9% compared to 62.7% with standard treatment. Remission rates were 73.8% versus roughly 50%.
A 2023 integrative review of 51 studies found that virtually all randomized controlled trials with frequent symptom feedback significantly improved outcomes, while infrequent assessments showed no benefit. The benefits include higher remission rates, lower relapse risk, improved medication adherence, and stronger therapeutic alliance.
Despite this evidence, only about 18% of psychiatrists implement measurement-based care routinely. The main barrier is perceived time burden, but between-appointment digital assessments actually reduce time spent on data gathering during visits.
What between-appointment monitoring provides
Without between-appointment data, psychiatrists miss critical information:
Symptom trajectories. Did depression improve steadily, partially improve then plateau, or get better then worsen? Standard visits show endpoints only, not paths.
Side effect patterns. A patient who experiences activation and insomnia for two weeks after starting an SSRI, then adjusts, may report "no problems" at follow-up. That information affects future prescribing.
Adherence signals. Patients don't always take medications as prescribed. Without data, non-adherence looks like non-response.
Early warning signs. A patient whose scores climb between appointments may be heading toward relapse. Without tracking, this isn't detected until the next visit, which may be too late.
How it works in practice
Patients complete standardized assessments, such as the PHQ-9, GAD-7, or other relevant measures, at regular intervals between appointments.
Frequency depends on clinical status. Weekly during medication initiation or dose changes. Biweekly for patients in active treatment. Monthly for stable maintenance patients. At minimum, current data should arrive 48 hours before each visit.
Alerts flag concerning changes. A 5-point increase on the PHQ-9 warrants outreach before the scheduled appointment. Scores above threshold (PHQ-9 ≥15) trigger review regardless of change. Any positive response on suicide items generates immediate alert.
Pre-appointment review transforms visits. Instead of spending the first ten minutes reconstructing what happened since last time, the psychiatrist opens with concrete data. "Your PHQ-9 dropped from 18 to 12 over the past month. Tell me what you've noticed."
Clinical applications by treatment phase
Medication initiation. Side effects often peak in the first two weeks. Weekly assessments capture these issues while they're occurring. Response trajectories show whether improvement is gradual or absent, guiding dose adjustment decisions at week 4.
Treatment optimization. Monthly tracking for stable patients catches gradual deterioration before it becomes a crisis. Stable scores confirm medication continues working. Seasonal patterns become visible over time, enabling proactive adjustment.
Treatment resistance assessment. Systematic data documents that symptoms persisted despite adequate trials, supporting referral or authorization for augmentation. Adherence tracking distinguishes true non-response from inconsistent medication use. Partial response (30% improvement) informs decisions about augmentation versus switching.
Discontinuation monitoring. Symptoms often recur during or after tapering. Weekly tracking during this period catches relapse early. The timing and pattern of symptoms help differentiate medication withdrawal from illness recurrence.
What to measure
Core measures for most psychiatric patients:
- PHQ-9 for depression: 10 items maximum per assessment keeps completion rates high
- GAD-7 for anxiety
- Condition-specific measures as needed: PHQ-15 for somatic symptoms, insomnia scales for sleep
Side effect monitoring should include standardized checklists covering common concerns: sexual function, weight changes, sleep quality, and medication-specific issues.
Adherence questions, such as doses taken as prescribed, missed doses and reasons, complete the picture.
Getting started
Start simple. PHQ-9 and GAD-7 delivered 48 hours before each visit. Basic review workflow. This establishes the practice before adding complexity.
Expand gradually. Add between-appointment assessments once basic monitoring is working. Implement alerting for concerning scores. Include side effect monitoring.
Completion matters more than perfection. Keep assessments under 3 minutes. Send reminders. Explain the purpose: patients who understand why they're completing assessments complete them more reliably. Accept that some patients won't participate, and partial data still beats no data.
---
Between-appointment assessments give psychiatrists what brief medication visits can't: visibility into the weeks between encounters. The research shows this translates to better outcomes. Survey Doctor offers the PHQ-9, GAD-7, and 30+ other validated measures with automatic scoring and trend visualization. Create a free account to see how between-appointment monitoring works in practice.